InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,537.02
(
0.51%
)
US TECH 100
19,641.60
(
0.83%
)
Dow Jones
39,308.00
(
-0.06%
)
Brent Oil
86.91
(
-0.49%
)
Bitcoin
55,279.15
(
-3.01%
)
Post# of 252486
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119978
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: north40000 post# 250974

Wednesday, 03/06/2024 4:05:09 PM

Wednesday, March 06, 2024 4:05:09 PM

Post# of 252486
LEXX has a curious sequence of announcements vis-à-vis GLP-1. In Nov 2023, LEXX issued a PR with some scant data on pairing LEXX’s drug-delivery technology with NVO’s Rybelsus:

https://ir.lexariabioscience.com/news-events/press-releases/detail/229/lexarias-technology-improves-the-oral-performance-of-the

This Study is only meant to provide early-stage indicative information to Lexaria about the possibility of enhancing the pharmacokinetic ("PK") and pharmacodynamic performance of orally delivered GLP-1 drugs to assist in guiding the Lexaria team in additional investigations. This Study is not complete and additional results will be reported…

Yesterday, LEXX issued two PRs about animal studies, sending the stock up 33% today:

https://finance.yahoo.com/news/lexaria-begin-diabetes-weight-loss-140500945.html

Caveat emptor.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up